Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers. (15th October 2022)

• Record Type: Journal Article
• Authors: Pasman, Emily; Lee, Guijin; Kollin, Rachel; Rodriguez, Brooke; Agius, Elizabeth; Madden, Erin Fanning; Resko, Stella M.
• Is Part Of: Substance use & misuse. Volume 57:Number 12(2022)
• Page Start: 1828
• Page End: 1836
• Publication Date: 2022-10-15
• Subjects: Opioid use disorder -- medications -- providers -- attitudes -- methadone -- buprenorphine -- naltrexone; Narcotic habit -- Periodicals; Alcoholism -- Periodicals; Substance abuse -- Periodicals; Behavior, Addictive -- Periodicals; Sustance-Related Disorders -- Periodicals; 362.2905
• DOI: 10.1080/10826084.2022.2115853
• Languages: English
• ISSNs: 1082-6084

Abstract

Abstract: Background: Provider attitudes can be a powerful reinforcer of stigma toward medication for opioid use disorder (MOUD). This study examines attitudes toward MOUD among substance use treatment providers and identifies personal and professional characteristics associated with more positive attitudes. Methods: Treatment providers (N = 570) working at publicly-funded substance use programs in Michigan self-administered a web-based survey (November 2020 through July 2021), reporting their socio-demographics, professional experience, and attitudes toward MOUD. Linear regression was used to identify factors associated with general attitudes toward MOUD and three logistic regression models were calculated to identify factors associated with perceptions of each medication. Results: Half of providers considered methadone an effective treatment (53.0%); 62.9% considered buprenorphine effective, and 70.3% considered naltrexone effective. Receipt of training (B = 1.433, p = .009) and serving pregnant women or women with children (B = 1.662, p < .001) were associated with more positive attitudes toward MOUD. Providers with advanced degrees were more likely to consider methadone (OR = 2.264, p = .006), buprenorphine (OR = 2.192, p = .009), and naltrexone (OR = 2.310, p = .011) effective. Rural providers were more likely to consider naltrexone effective (OR = 2.708, p = .003). Providers working with criminal legal populations were more likely to consider buprenorphine (OR = 2.948, p = .041) and naltrexone (OR = 4.108, p = .010) effective, but not methadone. Conclusion: Treatment providers' attitudes remain poorly aligned with the evidence base. Increased efforts are needed to address attitudes toward MOUD among the specialized treatment workforce.